Factors related to loss of HIV-specific cytotoxic T lymphocyte activity
- PMID: 15090764
- DOI: 10.1097/00002030-200403050-00003
Factors related to loss of HIV-specific cytotoxic T lymphocyte activity
Abstract
Objective: To identify factors associated with loss of in vitro stimulated anti-HIV cytotoxic T lymphocyte (CTL) activity.
Methods: Immunological, virological and other characteristics of individuals who sustained anti-HIV CTL activity for prolonged periods with viral replication suppressed below detectable levels were compared with those that lost anti-HIV CTL activity under the same circumstances. Forty-four individuals, all but one receiving highly active antiretroviral therapy or combination therapy, were followed for 56 months. Virus load, lymphocyte counts, CD28 expression on CD8 T cells, in vitro restimulated HIV-specific CTL and T cell proliferation were assessed at regular intervals.
Results: Anti-HIV CTL responses were maintained throughout by 20 individuals with consistently detectable HIV replication and in 17 of 24 individuals with sustained suppression of HIV replication. As a group, the seven who lost anti-HIV CTL were older, had weaker baseline anti-HIV CTL activity, higher historical virus loads, lower historical and contemporary CD4 T cell counts and a lower percentage of CD8 T cells expressing CD28. Multivariate analysis suggested that CD4 T cell counts and anti-HIV CTL amplitude at study onset were independently associated with CTL loss in these individuals, as was percentage of CD8 T cells expressing CD28 at study's end. There was a significant direct correlation between nadir CD4 T cell counts and duration of anti-HIV CTL persistence after suppression of viral replication.
Conclusions: Most HIV-infected individuals retain CD8 anti-HIV CTL with in vitro proliferative potential, even when antigen is limited. Those who lose HIV-specific CTL responses generally show past or current evidence of severe disease progression or activity.
Similar articles
-
Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells.J Clin Immunol. 2000 May;20(3):175-86. doi: 10.1023/a:1006633429087. J Clin Immunol. 2000. PMID: 10941825
-
HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30. doi: 10.1097/00042560-199909010-00003. J Acquir Immune Defic Syndr. 1999. PMID: 10534143
-
Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.HIV Med. 2005 Jul;6(4):278-83. doi: 10.1111/j.1468-1293.2005.00307.x. HIV Med. 2005. PMID: 16011533
-
Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.Cell Mol Biol (Noisy-le-grand). 1994;40 Suppl 1:45-8. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7950861 Review.
-
Human immunodeficiency virus interactions with CD8+ T lymphocytes.Curr HIV Res. 2008 Jan;6(1):1-9. doi: 10.2174/157016208783572008. Curr HIV Res. 2008. PMID: 18288969 Review.
Cited by
-
Human leucocyte antigen-Bw4 and Gag-specific T cell responses are associated with slow disease progression in HIV-1B-infected anti-retroviral therapy-naive Chinese.Clin Exp Immunol. 2013 Mar;171(3):298-306. doi: 10.1111/cei.12025. Clin Exp Immunol. 2013. PMID: 23379436 Free PMC article.
-
Th17 cytokines and the gut mucosal barrier.J Clin Immunol. 2010 Mar;30(2):196-203. doi: 10.1007/s10875-010-9368-7. Epub 2010 Feb 2. J Clin Immunol. 2010. PMID: 20127275 Free PMC article. Review.
-
Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC).Retrovirology. 2007 Aug 30;4:62. doi: 10.1186/1742-4690-4-62. Retrovirology. 2007. PMID: 17727734 Free PMC article.
-
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.Front Immunol. 2021 Nov 11;12:767370. doi: 10.3389/fimmu.2021.767370. eCollection 2021. Front Immunol. 2021. PMID: 34858423 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous